PHARMADAX

Serial Number 87952390
Registration 6119507
700

Registration Progress

Application Filed
Jun 7, 2018
Under Examination
Jan 1, 2019
Approved for Publication
Nov 6, 2018
Published for Opposition
Nov 6, 2018
Registered
Aug 4, 2020

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2020-08-04)
Due: Aug 04, 2026 364 days

Trademark Image

PHARMADAX

Basic Information

Serial Number
87952390
Registration Number
6119507
Filing Date
June 7, 2018
Registration Date
August 4, 2020
Published for Opposition
November 6, 2018
Drawing Code
5000

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 4, 2020
Registration
Registered
Classes
005

Rights Holder

Pharmadax USA, Inc.

03
Address
340 S. Lemon Ave #4626
Walnut, CA 91789

Ownership History

Pharmadax USA, Inc.

Original Applicant
03
Irvine, CA

Pharmadax USA, Inc.

Owner at Publication
03
Irvine, CA

Pharmadax USA, Inc.

Original Registrant
03
Walnut, CA

Legal Representation

Attorney
Scott E. Benfield

USPTO Deadlines

Next Deadline
364 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-08-04)
Due Date
August 04, 2026
Grace Period Ends
February 04, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

37 events
Date Code Type Description Documents
Jun 28, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jun 28, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jun 28, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jun 28, 2021 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Jun 28, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 28, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Aug 4, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 30, 2020 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jun 27, 2020 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jun 24, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 24, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 24, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 21, 2020 ALIE A ASSIGNED TO LIE Loading...
Jun 12, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 15, 2020 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Jan 15, 2020 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jan 15, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 9, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 8, 2020 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jan 8, 2020 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jan 8, 2020 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Dec 30, 2019 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Dec 30, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 30, 2019 EXT2 S SOU EXTENSION 2 FILED Loading...
Dec 30, 2019 IUAF S USE AMENDMENT FILED Loading...
Jul 2, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 28, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 28, 2019 EXT1 S SOU EXTENSION 1 FILED Loading...
Jun 28, 2019 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 1, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 6, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 6, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 17, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 26, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 25, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 14, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 11, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
First Use Anywhere: Mar 1, 2016
First Use in Commerce: Mar 1, 2016

Additional Information

Design Mark
The mark consists of the word "PHARMADAX" in capital letters with "PHARMA" in bold letters and "DAX" in non-bold letters.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005